Navigation Links
Jiangbo Pharmaceuticals, Inc. to Present at CCG IR's China Rising Conference in New York
Date:5/12/2009

LAIYANG, China, May 12 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company") (which recently changed its name from Genesis Pharmaceuticals Enterprises, Inc.; OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced today that its management will present at the upcoming China Rising Conference hosted by CCG Investor Relations in New York, NY on May 18, 2009.

The date, time and location of Jiangbo Pharmaceuticals, Inc. presentation at the China Rising Conference are:

     Date:       Monday, May 18, 2009
     Time:       9:30 a.m. to 10:00 a.m. Eastern Time
     Presenter:  Ms Elsa Sung, Chief Financial Officer
     Venue:      The Yale Club
                 50 Vanderbilt Avenue
                 New York, NY 10017
     Webcast:   http://www.chinarisingconference.com/webcast.html

A replay of the webcast will be available for up to one year following the presentation using the same link.

The China Rising Investment Conference is hosted by CCG Investor Relations and will provide over 250 fund managers and investors access to senior management from a wide range of Chinese growth companies in sectors including consumer staples, agriculture, pharmaceuticals, infrastructure, information technology, advanced materials, capital goods, and alternative energy. The conference will include over 30 US-listed Chinese companies and a number of private companies.

Interested parties and investors can find more information for the conference by visiting CCG's China Rising conference website at: http://www.chinarisingconference.com .

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, and electuary (sticky syrup) form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Company Contact:
     Ms. Elsa Sung, CFO
     Jiangbo Pharmaceuticals, Inc.
     Tel:   +1-954-727-8435
     Email: elsasung@jiangbo.com
     Website:http://www.jiangbopharma.com/

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY office)
     Email: crocker.coulson@ccgir.com

     Graham Reed, Financial Writer
     Tel:   +1-646-213-1907
     Email: graham.reed@ccgir.com
     Website:http://www.ccgirasia.com

'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
2. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
3. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
5. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements
6. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-101, Potent Small Molecule for Treatment of Alzheimers Disease.
7. Jazz Pharmaceuticals, Inc. Announces Board of Directors and Management Changes
8. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
9. Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6.25% Convertible Senior Notes Due 2009
10. Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potency Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
11. Triax Pharmaceuticals, Providers of the No. 1 Prescribed Mid-Potentcy Corticosteroid Brand, Introduce a New Size of Locoid Lotion 0.1%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading ... the fourth quarter and full year ended December 31, 2015 on Monday, February 29, ... webcast for the investment community following the release at 4:30 PM ET. Investors interested ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in partnership ... Grand Challenge to generate a biomarker to track TDP43 aggregation. ... up to a $1 million investment. ... disease that affects nerve cells in the brain and the ... initiate and control muscle movement, which often leads to total ...
(Date:2/10/2016)... 10, 2016 Convergence scenarios are ... various technologies that results in diverse solutions ... opportunities create a cyclical system where technology ... the development of new technologies. ... technology convergences, which are constantly fostering new ...
Breaking Medicine Technology: